Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Kylin Therapeutics to Expand Cancer Research Efforts for Its Next-Generation RNAi Platform

Abstract:
Kylin Therapeutics, Inc., a developer of next-generation RNAi therapeutics, announced the expansion of its research and development efforts. The project will advance promising new RNAi cancer therapies. This expanded effort will be conducted at Purdue University's Bindley Bioscience Center, and will focus on further validating targeted, systemically delivered cancer therapies utilizing Kylin's proprietary pRNAi platform. "Our in vivo efforts have shown pRNAi to be a very potent and versatile RNA inducing platform," said Eric Davis, the president and CEO of Kylin. "This expanded effort will enable us to test the flexibility of the pRNAi platform against various cancer targets."

Kylin Therapeutics to Expand Cancer Research Efforts for Its Next-Generation RNAi Platform

WEST LAFAYETTE, IN | Posted on October 22nd, 2008

####

About Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. is a biotechnology company focused on the development of a novel platform technology called pRNA. pRNA is a discrete, RNA-based nanoparticle system. Kylin has re-engineered pRNA to induce RNA interference (RNAi). The resulting therapeutic platform is called pRNAi. This platform represents the next generation of RNAi-inducing therapeutics with superior pharmacokinetics and potency over siRNA.

For more information, please click here

Contacts:
Kylin Therapeutics, Inc.
Eric Davis, President and CEO
(765) 412-6661

Copyright © GlobeNewswire, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Renishaw receives Queen's Award for spectroscopy developments November 25th, 2014

JPK reports on the use of AFM and the CellHesion module to study plant cells at the University of Queensland November 25th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Nanomedicine

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014

ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014

An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014

Announcements

Renishaw receives Queen's Award for spectroscopy developments November 25th, 2014

JPK reports on the use of AFM and the CellHesion module to study plant cells at the University of Queensland November 25th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE